感染、炎症、修复
感染、炎癥、脩複
감염、염증、수복
INFECTION， INFLAMMATION， REPAIR
2014年
3期
169-173
,共5页
抗真菌药物%应用分析%消耗金额
抗真菌藥物%應用分析%消耗金額
항진균약물%응용분석%소모금액
Antifungal agents%Application analysis%Sales expenditure
目的：分析我院2010-2013年住院患者抗真菌药物使用情况及其变化趋势,为临床合理使用抗真菌药物提供参考依据。方法：采用消耗金额和用药频度(DDDs)排序法对我院2010-2013年住院患者抗真菌药物的使用情况进行统计分析,并计算药物的使用强度(AUD)和排序比。结果：2010-2013年我院抗真菌药物的消耗金额呈逐年上升的趋势,年平均增长率为24.14%。4年来吡咯类抗真菌药的消耗金额2010-2012年占第1位,2013年略低于棘白菌素类占第2位。吡咯类抗真菌药物在我院真菌治疗中占主导地位,其中伏立康唑的消耗金额逐渐取代伊曲康唑位居第1位；而伊曲康唑的用药频度一直占第1位。抗真菌药的用药强度呈下降趋势。结论：我院住院部抗真菌药物消耗金额所占抗感染药物金额比例呈上升趋势,用药强度呈下降趋势。住院患者抗真菌药物的使用结构、用药强度基本合理。伊曲康唑和伏立康唑仍是住院患者真菌感染的主要治疗药物,棘白菌素类抗真菌药的治疗效果也逐渐得到临床认可。
目的：分析我院2010-2013年住院患者抗真菌藥物使用情況及其變化趨勢,為臨床閤理使用抗真菌藥物提供參攷依據。方法：採用消耗金額和用藥頻度(DDDs)排序法對我院2010-2013年住院患者抗真菌藥物的使用情況進行統計分析,併計算藥物的使用彊度(AUD)和排序比。結果：2010-2013年我院抗真菌藥物的消耗金額呈逐年上升的趨勢,年平均增長率為24.14%。4年來吡咯類抗真菌藥的消耗金額2010-2012年佔第1位,2013年略低于棘白菌素類佔第2位。吡咯類抗真菌藥物在我院真菌治療中佔主導地位,其中伏立康唑的消耗金額逐漸取代伊麯康唑位居第1位；而伊麯康唑的用藥頻度一直佔第1位。抗真菌藥的用藥彊度呈下降趨勢。結論：我院住院部抗真菌藥物消耗金額所佔抗感染藥物金額比例呈上升趨勢,用藥彊度呈下降趨勢。住院患者抗真菌藥物的使用結構、用藥彊度基本閤理。伊麯康唑和伏立康唑仍是住院患者真菌感染的主要治療藥物,棘白菌素類抗真菌藥的治療效果也逐漸得到臨床認可。
목적：분석아원2010-2013년주원환자항진균약물사용정황급기변화추세,위림상합리사용항진균약물제공삼고의거。방법：채용소모금액화용약빈도(DDDs)배서법대아원2010-2013년주원환자항진균약물적사용정황진행통계분석,병계산약물적사용강도(AUD)화배서비。결과：2010-2013년아원항진균약물적소모금액정축년상승적추세,년평균증장솔위24.14%。4년래필각류항진균약적소모금액2010-2012년점제1위,2013년략저우극백균소류점제2위。필각류항진균약물재아원진균치료중점주도지위,기중복립강서적소모금액축점취대이곡강서위거제1위；이이곡강서적용약빈도일직점제1위。항진균약적용약강도정하강추세。결론：아원주원부항진균약물소모금액소점항감염약물금액비례정상승추세,용약강도정하강추세。주원환자항진균약물적사용결구、용약강도기본합리。이곡강서화복립강서잉시주원환자진균감염적주요치료약물,극백균소류항진균약적치료효과야축점득도림상인가。
Objective:To analyze the utilization of antifungal agents in patients admitted to the First Hospital Af-filiated to the Chinese PLA General Hospital during 2010 to 2013,and to provide references for clinical drug use. Methods:The data on utilization of antifungal agents in patients admitted to the First Hospital Affiliated to the Chinese PLA General Hospital during 2010 to 2013 were analyzed by sequencing the sales expenditure and defined daily dose system (DDDs)of antifungal agents,the antibacterial use density(AUD)and sequenced ratio were cal-culated. Results:During 2010 to 2013,antifungal sales expenditure showed an increasing trend,and the annual average growth rate was 24.14%. During 2010 to 2012,the annual average sales expenditure of pyrrole antifungal drugs was in the first place,and it was replaced by echinocandins in 2013. Pyrrole antifungal drugs were domi-nantly used in anti-fungi treatment. The sales expenditure of voriconazole gradually replaced itraconazole to be-come the first. However,the itraconazole kept on the top of DDDs list. The drug use intensity of antifungal a-gents showed a declining trend in these years. Conclusions:The sales of antifungal agents in in-patients showed a steady raise during 2010 to 2013 in our hospital. However,the drug use intensity is on the decline. In general,the structure and intensity of utilization of antifungal agents were rational on the whole. Itraconazole and voriconazole are still the major antifungal agents in the treatment of fungal infections of inpatients. At the same time,the treat-ment effectiveness of echinocandins is gradually recognized by clinicians.
